Diabetes & Substance Abuse in the Time of COVID-19 (Recorded Webinar)

This activity will address the urgent needs of patients with type 1 and type 2 diabetes who require complex diabetes treatment in the primary care setting in the time of COVID-19 by empowering and increasing the capacity of primary care providers (PCPs) and clinics to safely and effectively manage underserved patients who do not have access to routine specialty care. Led by a nationally/internationally renowned faculty team of diabetes experts (many of whom contribute to/co-author national guideline recommendations), this curriculum will spotlight various aspects of diabetes management for patients at high-risk for poor outcomes during the time of COVID-19. 

 Release Date: September 13, 2023
 Expiration Date: September 12, 2026
 Estimated Time to Complete: 52 mins
 Registration Fee: FREE

Originally recorded on 8/19/2020. View all Project ECHO Diabetes COVID-19 series information and resources HERE.

1. Describe why patients with diabetes are prone to substance use disorders (SUDs).
2. Review implications of COVID-19 on SUDs in patients with diabetes.
3. Identify the goals of care for patients with diabetes with active substance abuse disorders, and those in remission.
4. Discuss pharmacologic and other treatments for SUDs in the time of COVID-19.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

American Medical Association (AMA)
Stanford Medicine designates this Enduring Material for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. 

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: http://lane.stanford.edu/portals/cultural.html

Bibliography/Reference list:  Sources cited in the activity. Additional resources located at diabetescovid.stanford.edu

For activity related questions, please contact:
 Division of Pediatric Endocrinology and Diabetes
 Email: [email protected]

For CME general questions, please contact: 
 Email: [email protected]

Mitigation of Relevant Financial Relationships

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Justin Altschuler, MD
Sequoia MD

Faculty

Linda G. Baer, MSPH, CHCP
Director, ECHO Education & Coaches, Division of Pediatric Endocrinology & Diabetes
Stanford University Diabetes ECHO Hub

Faculty

Marina Basina, MD
Clinical Associate Professor
Stanford Health Care (SHC)

Faculty

Nothing to disclose

Matt Bouchonville, MD
Associate Professor
University of New Mexico School of Medicine

Faculty

Mary M. Bridgeman, PharmD, BCPS, BCGP
Clinical Associate Professor
Rutgers Ernest Mario School of Pharmacy

Faculty

Irwin Brodsky, MD, MPH
Attending Consultant
Maine Department of Health

Faculty

Kelly L. Close, MBA
Founder
diaTribe.org

Faculty

Nicolas Cuttriss, MD, MPH, FAAP
Director Project ECHO Diabetes COVID-19, Director Project ECHO Diabetes, Clinical Assistant Professor, Department of Pediatrics, Division of Endocrinology & Diabetes; Co-Founder & Chairman of the Board, AYUDA
Stanford School of Medicine

Faculty

Marisa Desimone, MD
Associate Professor of Medicine
SUNY

Faculty

Nicole Ehrhardt, MD
Assistant Professor of Medicine
The George Washington University, University of Washington Diabetes Insititute

Faculty

Leslie Eiland, MD
Assistant Professor, Division of Diabetes, Endocrinology & Metabolism
University of Nebraska Medical Center

Faculty

David N. Faldmo, PA-C, MPAS, CHCEF
Quality Director/Medical Director
Siouxland Community Health Center

Faculty

Magdelena Ford, MSN, APRN, FNP-C, CDES
Nurse Practitioner
Stanford Health Care (SHC)

Faculty

Samar Hafida, MD
Adult Endocrinologist/Instructor
Joslin Diabetes Center/ Harvard Medical School

Faculty

Korey Hood, PhD
Professor & Staff Psychologist
Stanford School of Medicine

Faculty

Consulting Fee-Insulet (Relationship has ended)|Consulting Fee-Cecelia Health|Consulting Fee-Lifescan Diabetes Institute (Relationship has ended)

Rohit Jain, MD
Assistant Professor of Medicine, Endocrinology
George Washington University

Faculty

Rayhan Lal, MD
Adult and Pediatric Endocrinologist
Stanford

Faculty

Paid consultant-Abbott Diabetes Care|Paid consultant-Biolinq (Relationship has ended)|Paid consultant-Capillary Biomedical (Relationship has ended)|Paid consultant-Deep Valley Labs (Relationship has ended)|Paid consultant-Gluroo|Paid consultant-Morgan Stanley|Paid consultant-Provention Bio (Relationship has ended)|Paid consultant-Tidepool|Paid consultant-PhysioLogic Devices

Dragana Lovre, MD
Assistant Professor
Tulane University, New Orleans, LA

Faculty

David Maahs, MD, PhD
Professor of Pediatrics and Chief of Pediatric Endocrinology
Stanford Medicine

Faculty

Advisor-Medtronic, Inc.|Advisor-lifescan (Relationship has ended)|Consulting Fee-abbott diabetes|Consulting Fee-aditxt (Relationship has ended)|Advisor-biospex|Consulting Fee-Sanofi-Aventis|Consulting Fee-Provention Bio (Relationship has ended)

Daniel Saltman, MD, FACP
Associate Clinical Professor
John A. Burns School of Medicine, University of Hawaii

Faculty

Eleni Sheehan, APRN
University of Florida

Faculty

Nothing to disclose

Jay H Shubrook, DO
Professor and Diabetologist
Solano County Famiy Health Services - Vallejo

Faculty

Advisor-Abbott Laboratories|Advisor-AstraZeneca|Advisor-Bayer Corporation|Advisor-Eli Lilly and Company|Advisor-NovoNordisk|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nevro

Savitha Subramanian, MD
Associate Professor of Medicine
University of Washington

Faculty

Marissa Town, RN, BSN, CDE
Clinical Research Manager
Stanford University

Faculty

Nothing to disclose

Ashby Walker, PhD
Director for Health Equity Initiatives
University of Florida Diabetes Institute

Faculty

Nothing to disclose

Christine Weir, BS
Stanford University

Faculty

This CME Series is supported in part by educational grants from Novo Nordisk and Pfizer, Inc.